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Abstract:
The purpose of this study was to evaluate the clinical conditions and cardiac
functions associated with left atrial (LA) fibrosis by late gadolinium enhancement
(LGE). LA LGE has been found to be associated with various measures of
cardiac functions, procedural outcomes, and adverse events in patients who
already have atrial fibrillation (AF). Assessment of LA fibrosis by LGE in patients
without AF has largely been unexamined and comparison of these patients to
those with AF could prove useful. This study was a retrospective chart and
imaging review of 137 consecutive subjects imaged with a 3D LGE sequence at
one institution from 2012-2014. Fibrosis by LA LGE is elevated in subjects with
congestive heart failure (CHF), AF, hypertrophic cardiomyopathy (HCM), and
mitral regurgitation when compared to a set of reference subjects (all p < 0.05).
In multivariate analysis, HCM (p = 0.01) and CHF (p < 0.01) were independently
associated with elevated LGE. Across all subjects, LA LGE was moderately
correlated with minimum LA volume (r = 0.41, p < 0.01) and LA ejection fraction
(r = -0.43, p < 0.01) but weakly correlated with maximum LA volume (r = 0.197, p
= 0.02); these relationships were similar in subgroups with and without AF. In a
subset of subjects without AF, there was a lower active atrial ejection fraction
with increasing LA LGE (r = -0.438, p < 0.01). Also, after multivariate adjustment
for ventricular filling measures, there was an independent association of
increased LA LGE with decreased passive LA emptying (p = 0.02). Subjects with
heart failure but ventricular ejection fraction >45% had greater LA LGE than
those with whose ejection fraction was <45% (p = 0.03).
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We found that extent of LGE correlates with the presence of CHF, AF, HCM,
mitral regurgitation, and some cardiac anatomic and functional measurements.
This study lays the groundwork for further evaluation of the utility of measuring
LA LGE in patients without AF.
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Introduction
Atrial Fibrillation: Prevalence and Pathogenesis
Atrial fibrillation (AF) is the most common sustained arrhythmia in patients
worldwide. In the United States, over 3 million people were estimated to have AF
in 2005 with a continuing increase in prevalence that could reach 7 million by
20501. AF has an incidence that increases with age and is associated with
symptoms of palpitations, dyspnea (when associated with congestive heart
failure

(CHF))

and

thromboembolic

disease.

The

increased

risk

of

thromboembolic disease results from ineffective atrial contraction caused by the
disorganized electrical activity in the atria and associated stasis of the atrial
blood. Stroke, visceral, and peripheral ischemia are significant contributors to AF
related morbidity and mortality. Clinical management of AF is based on either
heart rate or rhythm control, and management of thromboembolic risk with
anticoagulants such as warfarin or newer factor X inhibitors. This management
carries its own risk of bleeding, which must be carefully weighed against risks of
thromboembolism.
The pathogenesis of AF is related to a trigger (an abnormal focus of
electrical generation) and a substrate (the atria). It is known that the trigger is
closely associated with the pulmonary veins as electrophysiological studies have
determined this area is capable of repetitive firing, and the veins have been
found to be the site of stretch sensitive ion channels2,3. Once triggered, the
substrate must have some qualities that allow the electrical activity to persist, or
else it would self extinguish. Atrial tissue has a very short action potential

6

duration and a short refractory period that becomes even shorter with an
increasing rate of depolarization4. These qualities alone make the atria an ideal
site for maintaining aberrant electrical activity. Additionally, atrial remodeling is
thought to contribute to abnormal conduction pathways in the atria that lead to
the development of self-sustaining rotors of spiraling electrical activity3,4. While
some remodeling from other cardiac disease may contribute to the initial
development of AF, episodes of AF are known to contribute to remodeling in a
way that reinforces aberrant electrical activity5 and alters electrophysiological
properties of the atrial tissue6. This is why paroxysmal AF tends to progress to
persistent AF which then becomes harder to terminate and manage from the
physician’s standpoint.
Remodeling of the left atrium (LA) on pathology studies has been shown
to be associated with a variety of cardiac conditions, including AF5,7,8, mitral
regurgitation9,10, and CHF11. Many of these studies have been necropsy studies
or been done in animal models as, until relatively recently, there was no way to
quantify atrial fibrosis in vivo. As these conditions have significant overlap with
the clinical risk factors of AF development mentioned later, there could be
potential value in determining whether atrial fibrosis could be used as an
independent risk factor for later AF development or used as a guide to disease
management by a physician.
Left Atrial Fibrosis by MRI: Late Gadolinium Enhancement
Within the last 10 years, cardiac MRI sequences with late gadolinium
enhancement (LGE) have been developed that can examine atrial fibrosis12. To
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briefly discuss the imaging methodology, in MRI studies, gadolinium is
administered as a chelated ion that shortens the relaxation time of nearby
protons on T1 weighted sequences in the areas where the molecule in
concentrated. Immediately after IV administration, the concentration of
gadolinium is highest in the blood when compared to other tissues. However,
after time for mixing throughout the blood pool, the gadolinium compounds
redistribute into the extracellular space, particularly in regions of tissues that are
fibrotic or edematous. In cardiac imaging, scan parameters can be chosen that
“null” normal cardiac tissue causing it to have low signal intensity, while areas of
myocardium accumulating gadolinium have increased signal intensity. On an
image, these areas appear dark or bright (respectively). This technique has long
been used in cardiac MRI to examine regions of the ventricle affected by prior
infarction, sarcoidosis, and various other forms of cardiomyopathy.
Technical limitations of cardiac MRI limited the ability to use this technique
in the thin-walled atria until more recently. The heart is almost always in motion
either from its own electro-mechanical pumping function or nearby motion of the
lungs and diaphragm. Although there are times during the cardiac cycle when it
is moving less rapidly, this motion has always presented a challenge to the
spatio-temporal resolution of cardiac MRI, particularly in patients with arrhythmia.
To minimize these effects, gating techniques that utilize a subject’s EKG and
chest diameter ensure cardiac imaging data are acquired within a narrow range
of acceptable boundaries, in the current technique, when cardiac motion is
minimal. Additionally, many common MRI sequences acquire imaging data in an
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xy plane using phase and frequency encoding with a slice selection pulse. In
order to accurately identify and quantify late gadolinium enhancement in the
atria, data need to be acquired throughout the entire atria concurrently, which
requires encoding and acquisition in the x, y, and z dimensions simultaneously.
This 3D technique with the aforementioned gating to select for mid-late
ventricular diastole is used to image the entire left atrium for areas of T1
enhancement due to accumulation of extracellular gadolinium (see Figures 1B,
2).
LGE on cardiovascular MRI has been used to characterize areas of
fibrosis in the LA in patients with atrial fibrillation and has been associated with
various metrics and outcomes12,13. For example, LA LGE both before and after
pulmonary vein isolation is associated with rates of AF recurrence14,15. Areas of
LGE have been associated with lower endocardial voltage16,17. Additionally,
greater LA LGE has been found to be associated with stroke risk18, time in AF,
pattern of AF19, and changes in atrial functional measurements20. This LGE
detected fibrosis is suspected to underlie the remodelling previously described,
which leads to the persistence of aberrant electrical activity in the atria in patients
with AF. However, it has yet to be firmly demonstrated that locations of atrial
fibrosis are directly correlated with locations of self-sustaining rotors of electrical
activity.
Risk factors for Atrial Fibrillation
Current theory regarding the development and maintenance of AF is
complex but, as described above, is generally understood as an interaction
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between impulses generated by aberrant tissue in the region of the pulmonary
veins and a remodeled, fibrotic, and electrically susceptible atrial substrate3,5. LA
LGE is a noninvasive measurement of one of these AF drivers but its association
with risk of developing AF has not been described.
Many different clinical factors have been tied to the risk of developing
atrial fibrillation. The most common risk factor is hypertension but other factors
such as other heart disease, obesity, diabetes, hyperthyroidism, chronic kidney
disease, family history, heavy alcohol use, and pericardial fat, among others,
have been found to be associated with increased risk of having AF1,21-25. One
strongly associated cardiac lesion with AF is valvular disease, specifically mitral
stenosis and mitral regurgitation which have been found to be associated with
with a relative risk of AF as high as 2.42 (Table 1)26.
Age, LA size, CHF, and hypertrophic cardiomyopathy (HCM) also stand
out as particularly high-risk associations with AF21,26,27. There is also a general
association with these conditions and ventricular diastolic dysfunction, and the
link between diastolic dysfunction and AF has become better recognized
recently28. Although associated with AF, these other clinical factors have not yet
been associated with the primary development of atrial fibrosis by MRI.
Atrial function and ventricular dynamics
One correlate of atrial remodeling is atrial function, both passive and
active. Below we present data on the relationship between atrial function and
atrial fibrosis. However, any analysis of atrial dynamics cannot be considered
thorough without recognizing the importance of the link between left ventricular
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filling and left atrial emptying. Atrial emptying, like ventricular filling, happens in
three parts under normal physiologic conditions. 1) An early passive phase that
begins immediately after isovolumetric relaxation of the left ventricle when the
mitral valve opens and blood flows from a full left atrium to an “empty” left
ventricle. This flow of blood is very rapid. 2) A mid diastolic phase when blood
fills both the left atrium and ventricle from the pulmonary veins while the mitral
valve is open. The flow of blood through the valve is slow and this phase is also
called the conduit phase. 3) A late, active phase caused by contraction of the left
atrium which forces more blood into the left ventricle immediately prior to mitral
valve closure and ventricular contraction. Figure 3 displays the volume of the LA
during the cardiac cycle.
There are multiple well-established metrics for evaluating diastolic filling of
the left ventricle on echocardiography. These include the peak filling rate (PFR)
of blood flow through the mitral valve during early filling, the time from the
beginning of diastole until this peak occurs (time to PFR), the estimated time
from this peak until blood slows during mid diastole (deceleration time), ratios of
initial filling velocity to tissue movement (E/e’) and late filling velocity (E/A) are
just a few. Though well established for echocardiography, measures of diastolic
function for cardiac MRI are relatively new and attempt to quantify surrogates of
the echocardiographic measures because equivalent measures are challenging
to achieve on MRI (Figure 4)29. Consider flow velocity through the mitral valve.
While phase contrast imaging can be used to quantify flow through a plane that
includes the valve, this plane would need to change in order the accommodate

11

movement of the mitral valve during ventricular filling. This challenge limits the
utility of using this technique in clinical scanning, especially when an ultrasound
is cheaper and better able to measure flow with Doppler. Additional measures of
diastolic function on cardiac MRI are limited by temporal resolution or the use of
special tissue tracking techniques that have to be applied at the time of image
acquisition29.
The surrogates of echocardiographic diastolic function used in cardiac
MRI rest primarily upon changes in the volume of the left ventricle30. The ability of
cardiac MRI to accurately define ventricular volumes, detailing papillary muscles
and endocardial trabeculations, is one of the method’s strengths (Figure 5).
Although temporal resolution imposes some limitation on accuracy, ventricular
filling rates can be estimated from changes in ventricular volume over time and
be divided into the three phases mentioned earlier. Again, this is a surrogate for
directly measured flow velocities for a few reasons. One is that velocity through
the valve will be dependent on more than just the volume flowing through it and
will be related to parameters such as pressure gradients and valve area. Also,
this MRI approximation is a good surrogate only when aortic regurgitation is
minimal or non-existent so that this volume does not contribute significantly to the
end-diastolic volume. Regardless of their limitations, these measures of diastolic
function, discussed in the methods and discussion, are used in the current study
and the vast majority of studies, because they were the only ones available for
the most of our subjects.
Describing diastolic dysfunction
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Irrespective of the imaging modality used, combinations of these
measures have also been used to identify different stages and degrees of
diastolic dysfunction. From a physiological standpoint, diastolic dysfunction
progresses from impaired myocyte relaxation to reduced ventricular wall
compliance. Briefly, impaired relaxation leads to slower early filling rates with
relatively greater contributions from left atrial contraction. As the dysfunction
progresses, the ventricle begins to act like a stiffened spring, and after
contraction, the unusually thickened myocardium rapidly springs open and fills
quickly, early. Ventricular filling pressures are then high and relatively less blood
enters the ventricle during the mid diastolic, “conduit” phase. Atrial contraction
does little to contribute to ventricular end diastolic volume as it is pushing into a
stiffened

ventricle

under

higher

pressure.

These

changes

affect

echocardiographic measures in well-established, predictable ways that generally
allow for classification into grade 1, 2, or 3 diastolic dysfunction for a given
subject. Classification of diastolic dysfunction based on the surrogate MRI
metrics of diastolic dysfunction is new and less able to distinctly classify subjects
into each of the three established grades31. Regardless of this issue, cardiac MRI
studies have been able to show that increased left ventricular pressures, which
can occur with diastolic dysfunction, do affect left atrial emptying dynamics32.
This supports our hypothesis that diastolic dysfunction may also affect left atrial
fibrosis.
Among subjects with AF: the additional effect of mitral regurgitation
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Mitral regurgitation is a risk factor for the development of atrial fibrillation
likely mediated by its effect on atrial remodelling, increased volume, and fibrosis
development9,10,33. However, within AF subjects, the association of mitral
regurgitation with LA LGE is not well described. In spite of knowledge of the role
of mitral regurgitation in AF development, recent histopathology data of the left
atrial appendage of AF patients suggest that LA fibrosis is less prevalent in
subjects with mitral regurgitation compared to those with mitral stenosis34.
Further, another data set with few subjects does not show a relationship between
mitral regurgitation and LA LGE among AF patients35. We hypothesized that
increasing MR would result in increased LA LGE and examined this relationship
in a cohort with mitral regurgitation and AF.

Statement of Purpose/Aims
Despite its value in patients already found to have AF, patterns of LA LGE
in patients without AF have remained largely unexamined until very recently36.
Cochet el al found that, other than AF, LA LGE was associated with age and
structural heart disease36. In the current study, we examined the relationship
between LA LGE, particular clinical conditions, and measures of cardiac function
(atrial and ventricular, active and passive) in a population of patients with and
without AF. We hypothesized that patients with clinical risk factors of atrial
fibrillation such has CHF, HCM, enlarged LA, and ventricular diastolic dysfunction
would have increased LA LGE in addition to those with AF. We also
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hypothesized that increased atrial fibrosis would reduce the active and passive
emptying of the left atrium.

Methods
Patient Population and Clinical Data
This study was an IRB approved, retrospective review of all subjects imaged with
a late enhancement cardiac MRI sequence at our institution from 2012 to 2014.
Indications for imaging were diverse (Table 2) as this LGE sequence was
acquired as an added component of standard cardiac MRI protocols. After initial
identification of subjects in our PACS data-base, chart review of the electronic
medical record was conducted to extract subjects’ clinical information from
physician notes. Additionally, routine quantitative data describing cardiac
structure and function was obtained from the clinical imaging report including LV
end-diastolic volume (EDV), end-systolic volume (ESV), and ejection fraction
(EF). Of the 304 subjects initially identified, those who had a prior sternotomy or
catheter ablation of any type (28), or who were age 20 and younger (46), were
excluded. An additional 93 subjects were excluded due to assessment of poor
image quality (e.g. excessive motion artifact, poor contrast, or poor inversion time
choice), resulting in a final study population of 137 subjects.

Cardiac Imaging and Measurements
Cardiac imaging was performed on Siemens 1.5T MR scanners at our institution
(Aera, Siemens Healthcare, Erlangen Germany). The LA was imaged during mid
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ventricular diastole using an ECG-triggered and navigator-gated, fat-saturated
3D

gradient

echo

inversion

recovery

sequence,

15-25

minutes

after

administration of 0.2mmol/kg gadolinium contrast agent (Gadobutrol, Bayer
Healthcare, Leverkusen, Germany). Voxel size was 1.32 x 1.32 x 3.0 mm3 with
interpolation to 0.66 x 0.66 x 1.5 mm3.

Additional scan parameters were:

TR/TE/q= 5.3ms/2.1ms/15°. 25 views per segment were acquired, in a ky-centric
order.

LGE in the LA was described by its subjective presence or absence in 18
locations (4 around each pulmonary vein, the posterior wall, and the inter-atrial
septum), resulting in a semi-quantitative LGE score, which is scaled to 100
(Figure 1). Quantitative measurement of LGE volume was also performed using
a threshold of 3.5 SDs above the mean blood pool. Inter and intra rater reliability
of this method has shown to be good in other similar studies36 and all LGE
analysis was conducted by an experienced rater who was blinded to clinical data.
The volume of segmented LGE enhancement was obtained using summation of
segmented areas of enhancement in each axial slice (Figure 2).

Subjects were also imaged with cine steady state free precession two chamber
and four chamber views, and with a short axis stack of the left ventricle from the
apex to the base.

Scan parameters include: Balanced SSFP cine with

retrospective ecg-triggering, TR/TE/flip=3ms/1.5ms/60°, 30 cardiac phases. 1.4
x 1.4 x 8mm resolution. Measurements of the LA end-diastolic volume and LA
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end-systolic volume were approximated by the biplane area-length method37
(Figure 5b) and used to quantitate LA EF. An extension of this method was used
to estimate the total volume of LA tissue at end-diastole with an assumed
average left atrial wall thickness of 2.1mm38 and the surface area of the LA
modeled as a scalene ellipsoid. LA LGE volume as quantitated above was
divided by total LA tissue volume to calculate an LA fibrosis percentage.

Assessment of active and passive atrial function.
In a subset of the first 42 consecutive subjects in the entire cohort who did not
have AF, LA volume throughout the entire cardiac cycle was measured, also
using the biplane method. Only the first 42 of 101 total non-AF subjects where
used due to the time intensive nature of this method. Atrial emptying was divided
into passive and active phases based on changes in slope of the time volume
curve. The active and passive EF were then calculated (Figure 3)39.

In the

same subset, left ventricular volumes were also quantified using Simpson’s
method (summation of discs) across the cardiac cycle and used to construct a
ventricular volume vs. time curve with a MATLAB (The Mathworks, Natick MA)
spline fitting function. From this curve, a derivative curve was constructed and
used to calculate peak filling rate, time to peak filling rate, and early to late filling
rate ratio (E:A)30 (Figure 4). Percent length of diastole to recover 60% of
ventricular stroke volume (DVR) was calculated from the original volume vs time
curve. Contours used to calculate LV volumes did not include the most basal
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slice. These LV metrics of diastolic function were used to adjust for the wellknown impact of diastolic function on passive LA function.

Assessment of mitral regurgitant fraction (MRF)
In a subset that included all subjects with AF (n=35; one AF subject lacked a
phase contrast sequence), mitral regurgitation was quantified as a fraction of
ventricular stroke volume. To calculate this value, ventricular endocardial borders
were contoured at end systole and end diastole using a semi-automatic threshold
detection technique that excluded ventricular trabeculations and papillary
muscles from volume measurements. Because of the nature of this method for
determining mitral regurgitant fraction, it was essential to include the basal slices
of the heart when calculating these volumes. Similar to the above, Simpson’s
method was used to calculate the ventricular volumes from these contours and
the difference between these volumes was the stroke volume. Forward flow
through the aorta was quantified using phase contrast imaging during ventricular
systole. By process of exclusion in normal cardiac anatomy, ventricular stroke
volume that does not flow forward through the aorta must be flowing retrograde
through the mitral valve into the LA. As such, the mitral regurgitant volume is the
ventricular stroke volume minus the aortic forward flow, and was represented as
a percentage of the ventricular stroke volume.
All image post processing was done using Circle Cardiovascular Imaging
software v4.2 (Calgary, CA).
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Data Analyses
In this retrospective review, the clinical data gathered included sex, weight,
height, smoking status, and other attributes of past medical history with specific
attention to cardiovascular disease and risk factors. Not all study data was
available for all subjects, and subjects were included in each analysis only when
pertinent data were available in the record (Table 3). An incomplete record
resulted from some patients who were referred to this institution for imaging by
providers outside of the network; there is no chart in our EMR for such patients.
Finally a reference group was identified from the entire 137 member cohort using
a predetermined set of criteria: No structural or myopathic cardiac disease, no
atrial fibrillation, no more than mild mitral regurgitation, no diagnosed coronary
disease if subject has had a cardiac catheterization, LV EF >45%, and LV EDV
index <90 ml/m2. Twenty-three reference subjects fit these criteria. These were
usually subjects referred for work-up of suspected arrhythmogenic RV
cardiomyopathy or cardiac sarcoidosis whose MRI was negative for signs of such
pathology.
Statistics
In describing the relationship between LA LGE with clinical and cardiac variables,
LGE was analyzed as a percentage of estimated LA tissue volume and as a
semi-quantitative LGE score. Analysis using both metrics of LGE was done to
determine whether there are differences in the ability of each to find trends, as
each is different in its quantification of different patterns of LGE (see discussion).
Student’s t-tests were used to compare LGE tissue percentages among subjects
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with vs. without varying conditions while Mann-Whitney tests were used for
similar comparison of LGE scores. Pearson correlations were used to describe
the relationship between continuous variables such as age, LA volume, atrial and
ventricular emptying and filling measures, and LGE tissue percentage while
Spearman correlations were used for similar analyses of LGE score. A least
squares multivariate regression was used to describe the relationships of clinical
conditions with the percentage of LA LGE. Clinical conditions in the model were
chosen based on a threshold of p <0.1 in the univariate analysis. Separately,
multivariate adjustment for ventricular filling dynamics was made to describe the
relationship among LA LGE tissue percentage and atrial passive emptying.
Similar analysis of ventricular filling and atrial emptying was conducted using
LGE score quartiles. Square root or logarithmic transformations were used to
allow for parametric analysis of otherwise non-normally distributed continuous
data. All statistical analyses were performed using JMP v11 (SAS Institute, Cary
NC).
Contributions of colleagues
Dana Peters: Provided initial direction of research inquiry, provided data from
pilot study, quantified LGE score and LGE tissue percentage, provided ongoing
feedback regarding analyses and future directions
Lauren Baldassarre: provided continuing feedback on direction of the project,
verified phase contrast forward flow measures and ventricular contours for
calculating stroke volumes and mitral regurgitant fractions.
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Karl Grunseich: Conducted all other aspects of the project including: expanding
scope of the research question, identification of new subjects, clinical chart
review, imaging report review, contouring of the atrial and ventricular borders of
subjects in each respective analysis, post-processing of atrial and ventricular
volume-time data, all statistical analysis.

Results
Measurement of LA LGE: Quantitative vs. Semi-quantitative.
Our two measurements of LA LGE are not equivalent to each other. LA LGE
scores are more representative of the distribution of fibrosis across the LA; they
indicate the percentage of 18 different possible regions that show enhancement.
Left atrial fibrosis percentage is a measurement of volume of enhanced tissue
relative to total atrial tissue. This measure may represent a single large area of
enhancement in a way that is similar to many small, scattered regions of
enhancement. Although these measurements indicated different aspects of the
enhancement pattern, they are strongly correlated to each other (rs = 0.699, P <
0.001 Figure 6). The fully quantitative method required ~5 minutes of analysis,
vs. <1 minute for the semi-quantitative method.

Association with clinical conditions
The study population was 59% male, with a mean age 51.3 (SD 13.8), a mean of
BMI 28.5 (SD 5.9), and a diverse distribution of cardiovascular disease and risk
factors (Table 3).
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LGE percentage
There is a moderate but significant correlation between age and percentage of
atrial tissue enhancement (r = 0.359 p < 0.001). In univariate analysis of each
clinical factor considered within the entire cohort, only subjects with CHF or any
mitral regurgitation had greater percentage of LA tissue enhancement than those
without those conditions (Table 4a). In a multivariate regression including HCM,
CHF, AF and mitral regurgitation, HCM and CHF were independently associated
with increased LA LGE (Table 4b). Continuous variables of age and LA EF were
not included in the multivariate analysis as they are closely associated with CHF
and AF, causing concerns of multicollinearity. When compared to the relatively
healthy reference subjects, those with HCM, CHF, greater than mild mitral
regurgitation and AF all had significantly higher LA LGE tissue percentages
(Table 5, Figure 2). We did not find any relationships with risk factors of
cardiovascular disease, such as hypertension, obesity, or diabetes, and LA LGE.
LGE Score
There is a weak, non-significant correlation between age and LGE score (rs =
0.147 p = 0.087). In univariate analysis of each clinical factor considered within
the entire cohort, only subjects with CHF or HCM had greater percentage of LA
tissue enhancement than those without those conditions (Table 6). A multivariate
regression including HCM and CHF had a statistically significant lack of fit test (p
= 0.042). Continuous variables of LA EF or LA volumes were not included in the
multivariate analysis as they are closely associated with CHF, causing concerns
of multicollinearity. When compared to the relatively healthy reference subjects,

22

those with HCM, CHF, greater than mild mitral regurgitation and AF all had
significantly higher LA LGE scores (Table 5, Figure 2). We did not find any
relationships with risk factors of cardiovascular disease, such as hypertension,
obesity, or diabetes, and LA LGE score.

Association with atrial size and function
LGE percentage
Across all subjects, there was a weak to moderate but significant correlation
between both maximum and minimum LA volume and LA LGE percentage
(Figure 7,Table 7). These relationships were also similar for subjects with and
without atrial fibrillation (Table 7). Additionally, there was a moderate correlation
between overall LA ejection fraction and LA LGE percentage that was similar in a
subset of subjects with and without atrial fibrillation (Table 7).
LGE Score
Across all subjects, there was a weak to moderate but significant correlation
between both maximum and minimum LA volume and LA LGE score (Figure 7,
Table 7). These relationships were also similar for subjects with and without atrial
fibrillation, although statistical significance was not achieved from AF subjects
(Table 7). Additionally, there was a moderate correlation between overall LA
ejection fraction and LA LGE score that was similar in a subset of subjects with
and without atrial fibrillation (Table 7).

Association with ventricular functions
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LGE percentage
In a subset of 42 subjects without AF, there was no direct relationship between
peak filling rate, time to peak filling rate, and proportion of diastole to 60%
diastolic volume recovery with LA LGE tissue percentage (r = -0.168 p = 0.288, r
= 0.036 p = 0.820, r = 0.139 p = 0.380 respectively). There were strong
correlations between both ventricular peak filling rate and time to peak filling rate
with passive atrial ejection fraction (r = 0.723 p < 0.001; r = -0.502 p < 0.001
respectively). Increasing LA LGE tissue percentage and peak filling rate were
independently associated with decreasing and increasing passive LA EF
respectively, while time to peak filling rate was not (Table 8). There was also a
lower active atrial ejection fraction in subjects with increasing LA LGE tissue
percent (r = -0.438 p = 0.004).
There was no relationship between LV EF and LA LGE (r = 0.071 p=0.418).
However, among patients with CHF and preserved EF (EF>45%) there was
greater LA LGE percentage compared to those with lower LV EF (p = 0.032,
Figure 8).
LGE Score
There was no direct relationship between LGE score and markers of diastolic
dysfunction (including PFR, time to PFR, or proportion of diastole to 60%
diastolic volume recovery; rs = 0.072 p = 0.653, rs = -0.015 p = 0.925, rs = -0.067 p
= 0.675 respectively). After adjustment for the relationship of PFR and time to
PFR with passive atrial EF, those subjects in the highest LA LGE quartile had
lower passive atrial ejection fraction when compared to those in the lower two LA
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LGE quartiles (p=0.020; Figure 9). In multivariate analysis, PFR (p < 0.001) but
not time to PFR (p = 0.063) was independently associated with passive LA EF.
There was also a lower active atrial ejection fraction in subjects in the highest
compared to the lowest LA LGE quartile (p = 0.047).
There was no relationship between LV EF and LA LGE score (rs = -0.032 p =
0.711). Among patients with CHF and preserved EF (EF>45%) there was no
difference in LA LGE score compared to those with lower LV EF (p = 0.085).

Association of LGE with mitral regurgitation in subjects with AF
In a sub-study of 35 AF subjects, we investigated the hypothesis that AF patients
have greater remodeling in the presence of mitral regurgitation (MR). Subject
characteristics were 69% male, mean age 56.4±10.1, mean BMI 30.0 ±5.3, 51%
hypertensive, 20% congestive heart failure, and 14% diabetic. MR was visualized
in 60% of subjects (16 mild, 3 moderate, 2 not described). The presence of visual
MR was associated with increased maximum LA volume (p = 0.001) and
increased MRF (p = 0.022, Figure 10). Maximum LA volume was poorly
associated with quantitative MRF (r = 0.232, p = 0.186).
LGE percentage
The presence of visual MR was not associated with higher LA LGE percentage
(p = 0.307). Maximum LA volume was weakly and not significantly associated
with LA LGE percentage (r = 0.221, p = 0.201). Direct association between MRF
and LA LGE percentage (r = 0.129 p = 0.467) was not observed. Adjustment for
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LA volume did not impact the relationship between MRF and LA LGE percentage
(rp = 0.108 p = 0.590).

LGE Score
The presence of visual MR was not associated with higher LA LGE score (p =
0.672). Maximum LA volume was not associated with LA LGE score (rs = 0.146,
p = 0.402). Direct association between MRF and LA LGE score (rs = 0.140 p =
0.430) was also not observed. After adjustment for LA volume, increased MRF
was not correlated with LA LGE score (rp = 0.047 p = 0.803).

Discussion
Quantitative vs. semi-quantitative assessments
The quantification of LA LGE remains a relatively controversial area within the
field of cardiac MRI. The current “gold standard” involves contouring the
endocardial and epicardial border of the atrial tissue in each axial reconstructed
slice. The enhancement threshold above the blood pool is then applied to the
contoured atrial tissue, and both the enhanced and unenhanced areas are
summed across all slices to calculate the fraction of atrial tissue that is
enhanced. This process is incredibly time intensive and, if the service is provided
by a third party, expensive. In this study we used two different methods of LGE
quantification of varying simplicity. The tissue percentage we calculated in this
study approximates the gold standard by estimating the volume of the total atrial
tissue, which serves as a denominator for the fraction of enhanced tissue; the

26

volume of the enhanced tissue is calculated directly. This measure does not
distinguish well between a single large area of fibrosis and several smaller,
scattered areas of fibrosis, but is a relatively robust indicator of total atrial fibrosis
burden. The LGE score we used is more subjective, as it is based on an
experienced rater’s interpretation of enhancement in 18 pre-determined regions
of the LA. It also is a better indicator of the overall spacial extent of LA LGE, but
may understate one or two large but confined areas of LGE. This score
assessment can be made relatively quickly, easily, and without the expense of
external proprietary processing. The ultimate goal of this research is for the LA
LGE protocol to be used clinically if the sequence is found to add value to patient
prognosis and management. These features of the LGE score make it an
attractive measure in the clinical arena.

We found there to be a strong correlation between the two LA LGE measures
used in this study. This indicates that subjects with an increased amount of LA
LGE tend to have that LGE be distributed broadly throughout the LA instead of
confined to one or two regions. This agreement also gives support to the use of
the LGE score as an easier method of LGE quantification. However, there were
some differences in the conditions and functional metrics each measure of LGE
was associated with. On univariate analysis for example, LGE score was
significantly greater in subjects with HCM while LGE percentage was not. Also,
LGE percentage was greater in subjects with mitral regurgitation and marginally
with AF while LGE score was not. This type of discrepancy may indicate
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differences in how atrial fibrosis is distributed in the LA among these conditions.
For example, subjects with mitral regurgitation may not have a wider distribution
of LGE in the LA than those without, but do have more LGE in the regions where
they do have enhancement. Also, subjects with HCM do have greatly elevated
LGE scores that indicated the atrial fibrosis is wide-spread, rather than confined
to one area as could be interpreted from the LGE percentage.

It is important however, not to overlook how the subjective nature of the LGE
score and the multitude of statistical tests done on this data set, which may
increase the odds of false positive results. A decision was made not to use a
Bonferroni correction in these analyses because this would severely limit our
ability to find any differences in this relatively small population in a largely
hypothesis generating study meant to guide future research. In order to avoid
confusion for the remainder of the discussion, results referenced will be from the
slightly more quantitative and robust LGE percentage.

Atrial LGE, Clinical Conditions, and Cardiac Structure
The main finding of this study is an increased extent of atrial LGE in patients with
CHF, HCM, mitral regurgitation, and/or AF compared with the control group. In
pathology studies, many of these cardiac diseases have been individually
associated with increased atrial fibrosis. For example, LA fibrosis and
electrophysiological remodeling have been demonstrated to provide a substrate
for the development and persistence of AF11. Heart failure without AF is also
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associated with atrial fibrosis by pathology40, and it is known that CHF is
associated with increased incidence of AF with prevalence as high as 44%41 in
this group of patients. Previous studies of atrial fibrosis by LA LGE have nearly
exclusively examined patients with AF. A recent study did find a correlation of
LGE with structural heart disease in general but did not focus on specific disease
states36. In this study, we demonstrated that atrial fibrosis can be detected by LA
LGE MRI in subjects without AF who have CHF, HCM, or mitral regurgitation, a
finding which could have implications for future management of patients with
these conditions.

Atrial LGE is only mildly associated with maximum LA size, but moderately
associated with minimum LA size and LA EF in this study. Prior studies have
shown that minimum atrial volume is a stronger correlate with AF development,
adverse cardiovascular events, and NT-proBNP, compared with maximum
volume42-44. Similarly, minimum atrial volume is more strongly correlated with
atrial LGE in this study.

Although a relationship with atrial volume exists, LA LGE is not simply a
surrogate for LA volume. Factors such as atrial size have been shown to be tied
with outcomes in patients with heart failure45 and LA LGE could provide
additional new prognostic or decision guiding data in the management of these
patients that LA size alone does not. For example, within AF subjects Daccarett
et al.18 demonstrated increased predictive value of LA LGE beyond the CHADS2
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score for determining stroke risk. Analogously, the risk of developing AF in CHF
patients could include LA LGE as a valuable predictor. Also, ACE inhibitors can
reduce atrial fibrosis and mitigate the risk of AF development46. The presence of
LA LGE in a patient without AF could be a factor in selecting patients who would
benefit from initiating these drugs or in dose adjustment for patients who are
already taking them. These possible prognostic and clinical uses for measuring
LA LGE need further study.

Although there were a small number of subjects with HCM, those subjects had
substantially higher LA LGE percentages compared to others in the reference
group. To date, studies of LGE in hypertrophic cardiomyopathy have primarily
been limited to ventricular LGE. Such studies have shown ventricular LGE to be
related to AF47 and diastolic dysfunction48,49. HCM in general has a strong
relationship with atrial fibrillation and heart failure, with increased LA size and
decreased LA function associated with particularly high AF risk27,50and worse
heart failure symptoms51. Measurement of LA LGE in this population of patients
could provide similar clinical value as for CHF regarding risk assessment,
management, and prognostic value. As with CHF, further study is needed in a
larger population of these patients to identify risks or prognosis independently
associated with LA LGE.

Cochet et al36 found age to be an independent predictor of LA LGE. We also
found that increasing age was associated with increased LA LGE, but this
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association was weaker. Since conditions associated with increased LA LGE
(CHF, AF) are also associated with increasing age, we were not able to establish
an independent effect of age due to concerns of multicollinearity. Additionally, we
were not able to establish an independent association of AF with LA LGE,
although LGE was greater in the AF group than the healthy reference group. This
may have been due to our relatively smaller cohort compared to other studies or
due to a cohort with more paroxysmal vs. persistent AF patients, as persistent AF
has been associated with greater LA LGE19. Our study also did not demonstrate
any direct relationship with other cardiovascular risk factors (e.g. hypertension or
hyperlipidemia) or subject sex with the burden of LA fibrosis by LGE. These
conditions may not be strongly associated with fibrosis on their own, or such an
association may not be able to be detected by LA LGE in a study of this size and
type.

Atrial LGE and Atrio-Ventricular Dynamics
The recognition of diastolic dysfunction as a potential risk factor for AF is gaining
strength28. Increased LA LGE in AF, HCM and CHF –all associated with diastolic
dysfunction—suggests that there may be a more general association of left
ventricular dynamics and LA LGE, especially as both the current and other
studies51 have demonstrated close association between ventricular function and
atrial filling and emptying dynamics. Across a diverse subset of patients without
AF, we demonstrated that LA LGE was associated with reduced active and
passive atrial ejection fractions, similar to what has been found in AF patients20.
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Additionally, in the study as a whole, there is an association of decreased overall
LA ejection fraction with increased LA LGE. Together these results suggest LA
LGE detected fibrosis is a marker of poor atrial function. In patients with altered
systolic or diastolic ventricular function, it may be development of atrial fibrosis
that further decreases the atrial contribution to overall cardiac function, potentially
contributing to patients’ heart failure symptoms. Our finding of increased LA LGE
in patients with heart failure but preserved LV EF supports this hypothesis.

Lack of correlation between diastolic function and atrial LGE
What remains poorly demonstrated is whether ventricular dysfunction itself can
be directly related to left atrial fibrosis. In the current study, we did not find a
direct correlation between ventricular diastolic filling parameters and LA LGE,
although we were limited by a smaller sample size and the retrospective nature
of this study. Initially, we had intended to establish the grade of diastolic
dysfunction for the subjects for whom we calculated the diastolic filling
parameters. However, this was not possible because we lacked the ability to
distinguish between normal diastolic filling and grade 2 or “pseudonormal”
diastolic filling. This problem arises because of how the measures of ventricular
filling change as diastolic dysfunction progresses. With impaired relaxation there
is an initial decrease in early peak filling rate and an increase in time to peak
filling rate. As diastolic dysfunction progresses and the ventricle stiffens, this
change reverses and the peak filling rate increases and time to peak filling rate
decreases. Because of this trend, there is a time in the progression of diastolic
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dysfunction when these numbers appear normal. In echocardiography, there are
well-established parameters based on measures of tissue movement that can
distinguish true from pseudo normal. Unfortunately, MRI currently lacks such
distinguishing measures as even the measures of diastolic dysfunction unique to
MRI, e.g. proportion of diastole to 60% diastolic volume recovery, change in a
way similar to time to peak filling rate. Once a reliable distinguishing measure is
established that can be applied to previously acquired images for MRI, it will be
useful to revisit this subject population and stratify the grade of diastolic
dysfunction and look for patterns of LA LGE.

MRF is not correlated with LGE among AF subjects
In examining the subjects with AF in our study, we did not find any measures of
mitral regurgitation to be associated with LA LGE score or tissue percentage. It is
well established that many patients with AF have LA LGE, and our intent was to
find whether mitral regurgitation moderates or amplifies the quantity of LA LGE in
these AF subjects. There is a growing body of literature of correlates of LA LGE
in AF studies much larger than ours which have found atrial functional measures,
time in AF, and pattern of AF to be associated with LGE quantity19,20. Given that
these factors are known to influence the amount of LGE in the LA, it is
reasonable for us not to find an association of mitral regurgitation without first
being able to adjust for these other factors (we lacked adequate data in this
retrospective analysis). This would especially be true if the effect of mitral
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regurgitation is relatively weak, as might be the case in our data set as most
subjects had mild, if any, regurgitation.

Conclusion
In assessments of LA LGE in a diverse population, we found that extent of LGE
correlates with the presence of CHF, AF, HCM, mitral regurgitation, and age,
though independence could be established only for CHF and HCM. We also
found moderate relationships between LA LGE and LA volume, LA active EF,
and LA passive EF, after accounting for ventricular diastolic function. Each of
these findings of association of LA LGE with cardiac conditions and functional
metrics lays the groundwork for further inquiry into the utility of measuring LA
LGE in subjects beyond those with AF.

In particular, a prospective study following patients with CHF or HCM with initial
and follow-up LGE images and quantification could be fruitful, especially if
patients were also followed with periodic holter monitoring to document
development of atrial fibrillation. Such a study could determine variables that lead
to greater progression of LGE burden and detect whether LGE burden is related
to risk of AF. An additional study could also include an analysis to examine
whether patients’ medications, such as ACE inhibitors, influence LGE burden.
With the results of this study, the need to further evaluate the value of LA LGE
certainly seem worthy of pursuit.
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A
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Figure 1. (A) Schematic of 18 regions in the LA used to quantify the presence
of LA LGE included Anterior Superior (AS), Posterior Superior (PS), Anterior
Inferior (AI), and Posterior Inferior (PI) regions around each pulmonary vein in
addition to the posterior wall and interatrial septum. (B) Sample LGE image
indicating two regions of enhancement (red arrows). Corresponding axial slice
and enhanced regions indicated in A. Without enhancement in other planes,
would have 2/18 segments or a score of 11 scaled to 100.
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A. Reference

C. HCM

B. AF

D. CHF

Figure 2. Four subjects with LA LGE, showing a single slice, and the 3D
rendering of LGE (red) and normal tissue (blue). Subject A is a relatively
healthy reference subject while subjects B, C, and D have atrial fibrillation,
hypertrophic cardiomyopathy, and congestive heart failure, respectively.
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Table 1. Independent Risk Factors for New Onset of Atrial
Fibrillation in Older Adults (adapted from Psaty et al.
Circulation 1997. 96:7 2455-61)
Variable
Alcohol, drinks/wk
Systolic BP, 10 mm Hg
Height, cm
Cholesterol, mmol/L
Age, y
Glucose, mmol/L
Valve disease
β-Blockers
Diuretics
Coronary disease
Cardiac injury score
FEV1, L

RR
0.96
1.11
1.03
0.86
1.05
1.08
2.42
0.61
1.51
1.48
1.01
0.75

95% CI
0.93-0.99
1.05-1.18
1.02-1.05
0.76 -0.98
1.03-1.08
1.03-1.13
1.62-3.60
0.41-0.91
1.17-1.97
1.13-1.95
1.00-1.02
0.59 -0.94

Left atrial size, cm
Black race

1.74
0.47

1.44-2.11
0.22-1.01
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Indexed LA Volume (mls/m2)

50

End Atrial Diastole (EAD)

40

Passive Emptying Frac;on =

Pre- atrial systole (PAS)

30

Ac;ve Emptying Frac;on =
Total Emptying Frac;on =

20

End Atrial Passive
Emptying (EAPE)
0
0.0

0.2

0.4

End atrial systole (EAS)
0.6

0.8

1.0

Fraction of R-R interval
Figure 3. Representative curve of LA volume during the cardiac cycle with
formulas used to quantify atrial functions.

EAD - EAPE
EAD
PAS - EAS
PAS
EAD - EAS
EAD
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Figure 4. Representative curve of left ventricular volume (left) and its
derivative (right) during 30 phases (time points) of the cardiac cycle with
measures of diastolic function indicated. Diastolic volume recovery (DVR) is
the proportion of diastole required for the ventricular volume to return to X%
of the end diastolic volume. The “E” peak is the early peak filling rate (PFR),
the “A” peak is the filling rate during atrial systole.
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A

B

Figure 5. Screen capture of circle cardiovascular imaging software as used for
post processing to (A) determine left ventricular volumes over the cardiac
cycle and (B) estimate maximum (upper images) and minimum (lower images)
atrial volumes. Note the clear distinction of the endocardial border (red) and
papillary muscles (purple) in A. In B, the formula used to estimate volume is
Vol = 0.001 x (0.85 x 2 chamber atrial area (at left) x 4 chamber atrial area (at
right)/ 2 chamber length (yellow arrow).
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Table 2. Imaging Indications
Indication
Cardiomyopathy
Hypertrophic
Sarcoidosis/Infiltrative
Arrhythmogenic RV
General/Other
Atrial Fibrillation
Structural Disease
Myo/pericarditis
Mitral Regurgitation
Hemochromatosis
Other

N
9
39
26
20
29
11
7
4
2
12
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Table 3. Population Characteristics (N= 137)
Mean (s.d.)
N (%)
51.3 (13.8)
28.5 (5.9)

Age
BMI
Gender
male
81 (59%)
female
56 (41%)
Atherosclerosis Risk Factors
Tobacco Use
42 (37%)
Hyperlipidemia
53 (47%)
Hypertension
61 (48%)
Diabetes
14 (11%)
Selected Cardiac Disease
6 (4%)
Hypertrophic Cardiomyopathy
19 (14%)
Congestive Heart Failure
Atrial Fibrillation
36 (28%)
Mitral Regurgitation
52 (38%)
Medication Usage*
Beta-Blocker
48 (38%)
Calcium Channel Blocker
18 (14%)
ACE-Inhibitor
30 (23%)
Aspirin
45 (35%)
Statin
35 (27%)
Anti-arrhythmetic
17 (13%)
* at time of imaging
% considering only patients for whom data was
available

# Subjects
Missing
0
10
0
0
23
24
11
12
0
4
7
0
9
9
9
9
9
9
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x with AF
• without AF
• no data on AF

Figure 6. The quantitative LGE percentage of LA tissue volume is strongly
correlated to subjective, semi-quantitative LA LGE score (rs = 0.699 p < 0.001).
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Table 4a. Conditions and association with LA LGE tissue percentage. Data are means (+SE), p value for t-test
comparing subjects with (+) and without (-) a condition or characteristic.
Overall
AF
without AF
Condition
LGE %
p
LGE %
p
LGE %
p
Obesity

+
-

4.2 (0.6)
4.8 (0.7)

0.51

4.6 (1.0)
7.7 (2.1)

0.14

4.1 (0.8)
4.2 (0.7)

0.92

Gender

male
female

4.4 (0.6)
4.6 (0.8)

0.83

4.8 (0.8)
9.4 (3.5)

0.14

4.2 (0.8)
3.7 (0.6)

0.65

Tobacco Use

+
-

4.3 (0.9)
5.0 (0.7)

0.47

4.9 (1.6)
6.6 (1.4)

0.41

4.1 (1.0)
4.3 (0.7)

0.9

Hyperlipidemia

+
-

4.3 (0.7)
5.4 (0.9)

0.28

4.1 (1.1)
8.0 (1.8)

0.06

4.3 (0.8)
4.3 (0.9)

0.97

Hypertension

+
-

5.1 (0.8)
4.1 (0.7)

0.34

5.4 (1.6)
7.0 (1.5)

0.45

5.0 (0.9)
3.5 (0.8)

0.19

Diabetes

+
-

5.6 (1.5)
4.4 (0.5)

0.44

7.4 (2.5)
5.9 (1.2)

0.58

4.7 (2.0)
4.1 (0.6)

0.72

Hypertrophic Cardiomyopathy

+
-

10.5 (3.9)
4.2 (0.4)

0.09

N/A
6.1 (1.1)

N/A

10.5 (3.9)
3.7 (0.5)

0.06

Congestive Heart Failure

+
-

9.5 (1.6)
3.8 (0.5)

<0.01

10.1 (2.7)
5.3 (1.1)

0.08

9.1 (2.1)
3.4 (0.5)

<0.01

Atrial Fibrillation

+
-

6.1 (1.1)
4.0 (0.5)

0.06

N/A
N/A

N/A

N/A
N/A

N/A

Mitral Regurgitation

+
-

5.9 (0.9)
3.6 (0.5)

0.02

7.0 (1.8)
4.9 (1.1)

0.28

5.6 (1.1)
3.4 (0.6)

0.06

Atherosclerosis Risk Factors

Selected Cardiac Disease

Table 4b. Multivariate analysis of factors associated with LA LGE
Standardized
β
Hypertrophic Cardiomyopathy
0.209
Congestive Heart Failure
0.274
Atrial Fibrillation
0.151
Mitral Regurgitation
0.093
Model r2
0.173

p
0.013
0.002
0.081
0.297
<0.001
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Table 5. Median (IQ range) for LGE Score and Mean (+SE) for LA LGE percentage of tissue
volume for selected cardiac disease and comparison to reference group (Mann-Whitney test
or t-test).
LA LGE
LGE % of LA
Score
p
Tissue
p
Reference
11 (0-17)
2.1 (0.6)
Selected Cardiac Disease
Hypertrophic Cardiomyopathy
61 (38-74) <0.001
10.5 (3.9)
0.021
Congestive Heart Failure
33 (22-44) <0.001
9.5 (1.6)
<0.001
Atrial Fibrillation
17 (6-42)
0.013
6.1 (1.1)
0.001
Mitral Regurgitation
7.9 (2.8)
0.018
17 (6-33)
<0.001
note: reference group includes subjects with mild or no detectable mitral regurgitation
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Table 6. Conditions and association with LA LGE Score. Data are median (interquartile range), p value for MannWhitney test comparing subjects with (+) and without (-) a condition or characteristic.
Overall
AF
without AF
Condition
LGE Score
p
LGE Score
p
LGE Score
p
Obesity

+
-

11 (6-28)
17 (6-33)

0.35

17 (6-33)
28 (6-46)

0.30

11 (6-28)
17 (6-33)

0.57

Gender

male
female

17 (6-33)
17 (6-32)

0.76

17 (8-39)
17 (0-44)

0.63

11 (6-33)
17 (11-28)

0.49

Tobacco Use

+
-

11 (4-29)
17 (7-33)

0.24

11 (4-32)
19 (10-44)

0.27

11 (1-32)
17 (6-33)

0.51

Hyperlipidemia

+
-

11 (6-28)
17 (6-33)

0.44

17 (6-33)
28 (1-44)

0.70

11 (6-28)
17 (6-33)

0.52

Hypertension

+
-

17 (6-28)
17 (6-33)

0.71

17 (6-33)
28 (11-44)

0.20

17 (6-28)
11 (6-33)

0.87

Diabetes

+
-

11 (6-22)
17 (6-33)

0.65

17 (8-36)
17 (6-44)

0.96

11 (6-17)
17 (6-33)

0.44

Hypertrophic Cardiomyopathy

+
-

61 (38-74)
17 (6-33)

<0.01

N/A
17 (6-42)

N/A

61 (38-74)
17 (6-28)

<0.01

Congestive Heart Failure

+
-

33 (22-44)
14 (6-28)

<0.01

33 (22-44)
11 (6-33)

0.05

36 (15-43)
17 (6-28)

<0.01

Atrial Fibrillation

+
-

17 (6-42)
17 (6-33)

0.57

N/A
N/A

N/A

N/A
N/A

N/A

Mitral Regurgitation

+
-

19 (6-33)
17 (6-33)

0.32

22 (6-44)
17 (6-33)

0.77

22 (11-33)
17 (6-33)

0.27

Atherosclerosis Risk Factors

Selected Cardiac Disease

Figure 7. Associations of LA volumes and ejection fraction with measures of LA
x , --- with AF
LGE. See Table 7 for correlations.
•,
without AF
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Table 7. Correlation coefficients between LA size and function and measures of LA LGE. Spearman correlations for LGE Score and Pearson correlations for
LGE % tissue volume.
Overall (N=132)
AF (N=36)
Non-AF (N=89)
LA LGE %
LA LGE %
LA LGE %
LA LGE
tissue
LA LGE
tissue
LA LGE
tissue
Score
p
volume
p
Score
p
volume
p
Score
p
volume
p
Maximum LA volume
0.240
0.005
0.197
0.022
0.135
0.433
0.178
0.299
0.235
0.024
0.147
0.163
Minimum LA volume
0.346
<0.001
0.406
<0.001
0.279
0.099
0.349
0.037
0.385
<0.001
0.401
<0.001
LA Ejection Fraction
-0.281
0.001
-0.430
<0.001
-0.286
0.091
-0.446
0.007
-0.271
0.0104
-0.375
<0.001
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Table 8. Correlates of passive LA EF: multivariate analysis with LA LGE and
ventricular diastolic filling parameters. (N=42)
Standardized β Partial r2
P
LA LGE Percentage
-0.253
0.137
0.019
Ventricular Peak Filling Rate
0.580
0.384
<0.001
Time to Peak Filling Rate
-0.199
0.070
0.099
2
0.610
Model r
<0.001

53
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0
Preserved LV EF

Reduced LV EF

Figure 8. LA LGE in subjects with congestive heart failure. Those with normal or mildly
reduced left ventricular EF have greater LA LGE than those with EF < 45% (p=0.032).
Data are mean +S.E.
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0.5

Passive LA EF

0.4

*

*
†

0.3
0.2
0.1
0.0
1

2

3

4

LGE Quartile

1st = 0-6 2nd = 11-17 3rd = 22-33 4th = 39-100
Figure 9. After multivariate adjustment for peak filling rate and time to peak
filling rate, those subjects in the quartile with the highest LA LGE score had a
significantly lower passive LA ejection fraction than those in the lowest two
quartiles (p=0.020).
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Figure 10. Visualized mitral regurgitation is associated with both a greater
measured mitral regurgitant fraction (p=0.022) and indexed maximum left atrial
volume (p=0.001).

